Posted by Michael Wonder on 05 Feb 2023
AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
3 February 2023 - AstraZeneca's Imfinzi (durvalumab) has been approved by the MHRA to treat biliary tract cancer in combination with chemotherapy, the company announced.
The authorisation, which is specifically for adult patients with locally advanced, unresectable or metastatic biliary tract cancer, was issued under Project Orbis, an international programme to speed up the approval process of promising cancer drugs.
